OTCMKTS:RGRX RegeneRx Biopharmaceuticals - RGRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding RegeneRx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.12 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.12▼$0.1250-Day Range$0.11▼$0.1552-Week Range$0.10▼$0.25Volume200 shsAverage Volume9,083 shsMarket Capitalization$17.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest About RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) StockRegeneRx Biopharmaceuticals, Inc. engages in the development of a novel therapeutic peptide, Thymosin beta 4 for tissue and organ protection, repair, and regeneration. Its product pipeline includes RGN-259, RGN-352, and RGN-137. The company was founded by Allan L. Goldstein on May 13, 1982 and is headquartered in Rockville, MD.Read More Receive RGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RGRX Stock News HeadlinesMarch 1, 2023 | marketwatch.com2023 Biopharmaceutical Culture Media Market Top Countries Survey Predicts STRONG GROWTH bY 2029February 25, 2023 | marketwatch.comBiopharmaceutical Market 2023 ACCURATE PREDICTIONS with Fastest-Growing Segment till 2028March 26, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 24, 2023 | marketwatch.comBiopharmaceutical Market 2023: Market Specific Analysis and Perception Study for Players till 2027February 12, 2023 | finance.yahoo.comBiopharmaceutical Fermentation Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)January 31, 2023 | finance.yahoo.comThymosin Beta 4 Research Leads Toward Potential Future Anti-aging TherapyJanuary 27, 2023 | markets.businessinsider.com$3M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are BuyingJanuary 18, 2023 | marketwatch.comBiopharmaceutical Processing Equipment and Consumable Market Size in 2023 Share & Comprehensive Analysis till 2028 [ NEW REPORT ]March 26, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.January 17, 2023 | marketwatch.comBiopharmaceutical CMO & CRO Market Size 2023 with End-user Industries, Segments Covered in the ReportJanuary 3, 2023 | finance.yahoo.comPublication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic KeratopathyNovember 18, 2022 | finance.yahoo.comBiopharmaceutical Contract Manufacturing Market, 2035 - Shift from One-time Contracts to Strategic PartnershipsOctober 24, 2022 | finance.yahoo.comRegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye DiseaseSeptember 30, 2022 | investing.comClover Biopharmaceuticals Ltd (2197)September 27, 2022 | finance.yahoo.comRegeneRx Partner Submits Phase 3 Protocol for Neurotrophic Keratopathy (NK)August 22, 2022 | finance.yahoo.comRegeneRx Issues 2022 Letter To StockholdersJuly 18, 2022 | finance.yahoo.comRegeneRx Partner Signs LOI with Global Ophthalmology CRO for Two Phase 3 Clinical Trials in Neurotrophic KeratitisJune 22, 2022 | finance.yahoo.comRegeneRx Licensee to Expand Phase 3 Clinical Trial Program with RGN-259May 4, 2022 | finance.yahoo.comTβ4 Shows Potential as a Combination Treatment for Diabetes-Induced Complications of the CorneaFebruary 11, 2022 | finance.yahoo.comRegeneRx Consultant to Receive Prestigious Award for Contributions in Field of HealthFebruary 7, 2022 | nasdaq.comRGRX Real-Time QuotesJanuary 25, 2022 | finance.yahoo.comResearchers Confirm Thymosin Beta 4's Ability to Protect Eyes From Ethanol InjuryJanuary 20, 2022 | nasdaq.comRGRX After-Hours QuotesJanuary 12, 2022 | seekingalpha.comMicrocap RegeneRx surges 17% on regulatory development for ophthalmic candidateDecember 17, 2021 | finance.yahoo.comRegeneRx Joint Venture Will Hold Pre-BLA Meeting with FDA on February 28, 2022November 29, 2021 | finance.yahoo.comRegeneRx Joint Venture Requests Pre-BLA Meeting with FDA For RGN-259 for Dry Eye SyndromeOctober 29, 2021 | finance.yahoo.comClinical Results of RGN-259 for the Treatment of Neurotrophic Keratitis to be Presented at 2021 American Ophthalmology Association MeetingSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for RegeneRx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address RGRX Company Calendar Today3/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:RGRX Previous SymbolOTC:RGRX CUSIPN/A CIK707511 Webwww.regenerx.com Phone(301) 208-9191Fax301-280-1996Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,600,000.00 Net Margins-2,326.70% Pretax Margin-2,326.70% Return on EquityN/A Return on Assets-200.51% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual Sales$80,000.00 Price / Sales214.61 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-5.98Miscellaneous Outstanding Shares143,550,000Free Float125,606,000Market Cap$17.17 million OptionableNot Optionable Beta0.56 Key ExecutivesAllan L. GoldsteinChairman & Chief Scientific OfficerJ. J. FinkelsteinPresident, Chief Executive Officer & DirectorKey CompetitorsVincerx PharmaNASDAQ:VINCMolecular TemplatesNASDAQ:MTEMForte BiosciencesNASDAQ:FBRXBionomicsNASDAQ:BNOXABVC BioPharmaOTCMKTS:ABVCView All Competitors RGRX Stock - Frequently Asked Questions How have RGRX shares performed in 2023? RegeneRx Biopharmaceuticals' stock was trading at $0.1389 at the beginning of 2023. Since then, RGRX stock has decreased by 13.9% and is now trading at $0.1196. View the best growth stocks for 2023 here. What other stocks do shareholders of RegeneRx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other RegeneRx Biopharmaceuticals investors own include Biocept (BIOC), Fulcrum Therapeutics (FULC), Inpixon (INPX), OPKO Health (OPK), VBI Vaccines (VBIV), Vaxart (VXRT), AVEO Pharmaceuticals (AVEO), Palatin Technologies (PTN), Sorrento Therapeutics (SRNE) and Sierra Oncology (SRRA). What is RegeneRx Biopharmaceuticals' stock symbol? RegeneRx Biopharmaceuticals trades on the OTCMKTS under the ticker symbol "RGRX." How do I buy shares of RegeneRx Biopharmaceuticals? Shares of RGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is RegeneRx Biopharmaceuticals' stock price today? One share of RGRX stock can currently be purchased for approximately $0.12. How much money does RegeneRx Biopharmaceuticals make? RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) has a market capitalization of $17.17 million and generates $80,000.00 in revenue each year. How can I contact RegeneRx Biopharmaceuticals? RegeneRx Biopharmaceuticals' mailing address is 15245 SHADY GROVE ROAD SUITE 470, ROCKVILLE MD, 20850. The official website for the company is www.regenerx.com. The biopharmaceutical company can be reached via phone at (301) 208-9191, via email at info@regenerx.com, or via fax at 301-280-1996. This page (OTCMKTS:RGRX) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.